Altimmune, Inc. (ALT) SEC Filings — 2025
13 SEC filings for Altimmune, Inc. (ALT) in 2025.
Filings
- Altimmune, Inc. Files 8-K with Regulatory Updates — 8-K · Dec 19, 2025
- Altimmune Files 8-K: Board Changes and Financials — 8-K · Dec 1, 2025
- Altimmune Narrows Q3 Loss on R&D Cuts, Boosts Cash with Equity & Debt — 10-Q · Nov 6, 2025
- Altimmune Appoints New Directors, Updates Executive Compensation — 8-K · Oct 3, 2025
- Altimmune Files 8-K on Security Holder Vote — 8-K · Sep 25, 2025
- Altimmune's 2024 Executive Compensation & Equity Awards Detailed — DEF 14A · Aug 15, 2025
- Altimmune's Q2 Loss Widens to $35M Amid Continued ATM Offerings — 10-Q · Aug 12, 2025
- Altimmune Files 8-K on Financials — 8-K · Aug 12, 2025
- Altimmune, Inc. Files 8-K Report — 8-K · Jun 26, 2025
- Altimmune Q1 2025: Assets $77.8M, Liabilities $72.4M — 10-Q · May 13, 2025
- Altimmune, Inc. Relocates Principal Executive Offices — 8-K · Mar 13, 2025
- Altimmune, Inc. Files 2024 10-K — 10-K · Feb 27, 2025
- Altimmune Appoints Dr. Scott Harris as Chief Medical Officer — 8-K · Feb 25, 2025